The company that put the eye exam - and the eye treatment - inside a virtual reality headset. It started with one programmer's lazy eye. It ended up in clinical trials.
Here is a fact about lazy eye that most people find mildly upsetting: the conventional wisdom says you have to fix it in childhood, and if you miss the window, that is more or less that. James Blaha did not accept this. Blaha is a programmer, he has amblyopia and strabismus - the clinical names for a lazy, wandering eye - and in 2014 he did what programmers do when they distrust the received wisdom. He built something to test it.
The something was a piece of software that fed each of his eyes a slightly different image inside an early Oculus Rift development kit. The strong eye got a dimmed, quieter picture. The weak eye got a brighter, more demanding one. The idea, roughly, is that the brain has been ignoring the weak eye for years because it is easier to ignore it, and if you rig the game so that the weak eye is the only way to actually play, the brain has to start paying attention again. Blaha played his own game, and his weak eye improved - by his account, toward near-20/20. That is a strong result for a self-experiment, and it is the kind of result that turns a self-experiment into a company.
The company is Vivid Vision, it is based in San Francisco, and the elegant thing about it is that the medicine is indistinguishable from the entertainment. You put on a headset. You pop bubbles or chase objects or catch things flying at you. Meanwhile the software is quietly running a therapeutic protocol - adjusting contrast between your two eyes, nudging alignment, measuring what you can and cannot fuse into a single image. The patient experiences a video game. The clinician sees a vision therapy session. Both descriptions are true, which is the whole trick.
"The headset shows each eye a different image - often dimming what the strong eye sees - so the weaker eye is forced to work, and the brain relearns to use both eyes together."
Vivid Vision took this into the real world in 2015, launching a clinical suite for optometrists and ophthalmologists. This is a harder thing to do than it sounds, because eye-care clinics are not, historically, early adopters of consumer gaming hardware. But the pitch was good - vision therapy is real, it is also famously tedious, and a version of it that patients actually look forward to solves a problem that clinicians have complained about for a very long time. The suite treated thousands of patients in its early clinical years, and a prescribed at-home version followed so people could keep training between visits instead of only when they were sitting in a therapist's chair.
By the company's own accounting, the technology has now been used by more than 100,000 patients across more than 50 countries. That is a large number for a company treating a condition most people assume is untreatable in adults, and it is worth sitting with the implication: a lot of those patients are adults, well past the childhood window, using a headset to work on an eye they were told they were stuck with.
Now here is the part that is genuinely interesting from a business standpoint, and it is the kind of thing that happens more often than founders like to admit. Vivid Vision set out to treat eyes. Along the way, it built software that was extremely good at measuring them - because you cannot run an adaptive therapy game without constantly, precisely testing what the patient can see. And it turned out the measurement was the bigger business.
The product is called Vivid Vision Perimetry, or VVP. Perimetry is visual field testing - mapping the sensitivity of your retina point by point, the thing that flags glaucoma and macular degeneration and geographic atrophy. It is normally done on a large, expensive, dedicated machine in a clinic, with a patient hunched over an eyepiece clicking a button. VVP does it in a VR headset, and it can do it at home.
This matters to a specific and well-funded audience: pharmaceutical companies running clinical trials. Trials for eye diseases live or die on their endpoints - the measurements that prove a drug is working - and traditional perimetry is noisy, expensive, and dependent on patients showing up in person over and over. A 2025 study led by Dr. Karl Csaky at the Retina Foundation of the Southwest, supported by Regeneron, put VVP head-to-head against an in-clinic MAIA microperimeter. The at-home VR test did not just match the clinic machine. On fixation precision it was better - 0.55 degrees versus 1.2 - and participants completed close to 100% of their assigned sessions.
"Sometimes the product you ship reveals a bigger product you didn't know you had."
Read that adherence number again, because it is the quiet punchline. The single hardest thing in a clinical trial is getting human beings to reliably do a slightly annoying task, many times, on schedule. Vivid Vision's answer is that if the task feels less like an eye exam and more like a thing you put on and do, people actually do it. A headset that costs a fraction of a dedicated microperimeter, produces cleaner data, and gets near-total compliance is the sort of quiet cost inversion that reshapes an industry without anyone making a fuss about it.
The headset shows each eye its own image. Contrast and brightness are tuned independently - the strong eye is dimmed, the weak eye is emphasized.
The game is designed so you can only succeed by using both eyes together, forcing the brain to stop suppressing the weaker eye and start fusing the images.
The same engine that runs therapy runs precise visual field tests - the basis for VVP, the perimetry product now used as a clinical-trial endpoint.
The VR vision therapy suite for optometrists and ophthalmologists, treating amblyopia, strabismus, and convergence insufficiency through interactive, game-based exercises.
A doctor-prescribed home version so patients keep training between clinic visits - turning therapy from an appointment into a habit.
VR-based visual field testing precise enough to serve as a digital endpoint in trials for glaucoma, AMD, and geographic atrophy - at home or in clinic.
James Blaha builds a VR prototype to treat his own amblyopia (early on, tied to the name "Diplopia") and founds Vivid Vision.
The VR vision therapy suite ships to optometrists and ophthalmologists.
SoftTech VC, The VR Fund, and Liquid 2 Ventures back the platform's expansion.
A prescribed at-home version lets patients continue therapy between visits.
The company raises a Series A round to broaden its offering.
Vivid Vision Perimetry emerges as a VR visual field test aimed at clinical trials.
A Regeneron-supported study shows VVP matching and beating in-clinic microperimetry; the company is named a VSP Global Innovation Challenge finalist.
Vivid Vision builds VR software for two jobs: therapy for binocular vision disorders, and clinical-grade visual field testing. Its customers are eye-care clinics, their patients, and pharmaceutical trial sponsors.
It builds VR-based software for vision care - both therapy for binocular vision disorders like lazy eye and strabismus, and precise visual field testing (perimetry) used in clinics and clinical trials.
Programmer James Blaha, who has amblyopia himself, founded the company in 2014 after building a VR prototype that improved his own weak eye.
The headset shows each eye a different image - often dimming what the strong eye sees - so the weaker eye is forced to work, helping the brain relearn to use both eyes together.
VVP is a VR-based visual field / microperimetry test used as a digital endpoint in clinical trials for conditions like glaucoma, AMD, and geographic atrophy, and it can be run at home.
The company reports its technology has been used by more than 100,000 patients in over 50 countries, delivered through eye-care clinics and prescribed at-home programs.